WallStSmart

Mitsubishi UFJ Financial Group Inc ADR (MUFG)vsResMed Inc (RMD)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Mitsubishi UFJ Financial Group Inc ADR generates 108237% more annual revenue ($5.85T vs $5.40B). RMD leads profitability with a 27.5% profit margin vs 22.8%. MUFG appears more attractively valued with a PEG of 1.24. MUFG earns a higher WallStSmart Score of 72/100 (B).

MUFG

Strong Buy

72

out of 100

Grade: B

Growth: 7.3Profit: 6.5Value: 8.7Quality: 4.3
Piotroski: 7/9Altman Z: -0.34

RMD

Strong Buy

70

out of 100

Grade: B

Growth: 6.7Profit: 9.5Value: 8.7Quality: 8.3
Piotroski: 6/9Altman Z: 4.34
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MUFGUndervalued (+14.8%)

Margin of Safety

+14.8%

Fair Value

$21.96

Current Price

$16.96

$5.00 discount

UndervaluedFair: $21.96Overvalued
RMDUndervalued (+14.4%)

Margin of Safety

+14.4%

Fair Value

$303.30

Current Price

$226.31

$76.99 discount

UndervaluedFair: $303.30Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MUFG5 strengths · Avg: 9.2/10
Price/BookValuation
1.4x10/10

Reasonable price relative to book value

Operating MarginProfitability
34.8%10/10

Strong operational efficiency at 34.8%

Market CapQuality
$188.05B9/10

Large-cap with strong market position

Profit MarginProfitability
22.8%9/10

Keeps 23 of every $100 in revenue as profit

P/E RatioValuation
15.7x8/10

Attractively priced relative to earnings

RMD4 strengths · Avg: 9.5/10
Operating MarginProfitability
35.2%10/10

Strong operational efficiency at 35.2%

Altman Z-ScoreHealth
4.3410/10

Safe zone — low bankruptcy risk

Return on EquityProfitability
25.7%9/10

Every $100 of equity generates 26 in profit

Profit MarginProfitability
27.5%9/10

Keeps 28 of every $100 in revenue as profit

Areas to Watch

MUFG3 concerns · Avg: 2.0/10
Return on EquityProfitability
6.1%3/10

ROE of 6.1% — below average capital efficiency

Altman Z-ScoreHealth
-0.342/10

Distress zone — elevated risk

Debt/EquityHealth
3.771/10

Elevated debt levels

RMD0 concerns · Avg: 0/10

No major concerns identified

Comparative Analysis Report

WallStSmart Research

Bull Case : MUFG

The strongest argument for MUFG centers on Price/Book, Operating Margin, Market Cap. Profitability is solid with margins at 22.8% and operating margin at 34.8%. Revenue growth of 11.7% demonstrates continued momentum.

Bull Case : RMD

The strongest argument for RMD centers on Operating Margin, Altman Z-Score, Return on Equity. Profitability is solid with margins at 27.5% and operating margin at 35.2%. Revenue growth of 11.0% demonstrates continued momentum.

Bear Case : MUFG

The primary concerns for MUFG are Return on Equity, Altman Z-Score, Debt/Equity. Debt-to-equity of 3.77 is elevated, increasing financial risk.

Bear Case : RMD

No major red flags identified for RMD, but monitor valuation.

Key Dynamics to Monitor

RMD carries more volatility with a beta of 0.89 — expect wider price swings.

MUFG is growing revenue faster at 11.7% — sustainability is the question.

Monitor BANKS - DIVERSIFIED industry trends, competitive dynamics, and regulatory changes.

Bottom Line

MUFG scores higher overall (72/100 vs 70/100), backed by strong 22.8% margins and 11.7% revenue growth. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Mitsubishi UFJ Financial Group Inc ADR

FINANCIAL SERVICES · BANKS - DIVERSIFIED · USA

Mitsubishi UFJ Financial Group, Inc., a banking holding company, offers financial services in Japan, the United States, and Asia / Oceania. The company is headquartered in Tokyo, Japan.

Visit Website →

ResMed Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

ResMed is a San Diego, California-based medical equipment company. It primarily provides cloud-connectable medical devices for the treatment of sleep apnea (such as CPAP devices and masks), chronic obstructive pulmonary disease (COPD), and other respiratory conditions.

Visit Website →

Want to dig deeper into these stocks?